Ipsen (FR:IPN) has released an update.
Ipsen has entered into an exclusive global licensing agreement with Foreseen Biotechnology to develop, manufacture, and commercialize FS001, an innovative antibody-drug conjugate with the potential to be the first in its class, targeting a novel antigen present in a variety of solid tumors. FS001, which is in the final stages of preclinical development, has shown promising results in preclinical efficacy and safety, and Ipsen will spearhead its clinical trials and potential commercialization. This collaboration is expected to expand Ipsen’s oncology pipeline and leverage Foreseen’s proprietary proteomic platforms and AI-powered screening.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
